Digital Spatial Profiling Uncovers Transcriptomic Features of Distinct Plasma Cell-like Phenotypes in Diffuse Large B-cell Lymphoma - PubMed
4 hours ago
- #DLBCL
- #plasma cell-like phenotypes
- #spatial transcriptomics
- DLBCL exhibits significant heterogeneity, complicating treatment and prognosis.
- Four distinct plasma cell-like phenotypes are identified based on CD20, HLA-DRA, and PRDM1 markers.
- The CD20(+)HLA-DRA(+)PRDM1(-) phenotype is associated with better prognosis; the other three correlate with worse prognosis.
- Patients with >30% plasma cell-like phenotype cells are classified as DLBCL plasma cell-like phenotype predominant (DLBCLPCPP), with ≤30% as deficient (DLBCLPCPD).
- Plasma cell-like phenotype cells are linked to reduced proliferation, impaired immune function, and enhanced tumor microenvironment remodeling.
- DLBCLPCPP shows lower Ki-67 ≥85%, similar first-line treatment response, but higher disease progression within 12 months and more B2M alterations compared to DLBCLPCPD.
- Transcriptomic analyses reveal plasma cell-like phenotype cells are closer to plasmablastic lymphoma.
- A random forest model using plasma cell-like phenotype-associated genes predicts bortezomib response: high signatures link to poorer PFS but benefit from R-CHOP plus bortezomib, while low signatures benefit from R-CHOP alone.